Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye
The intervention in this trial is intraocular islet transplantation. A single dose of 1000 - 3000 Islet Equivalents (IEQ)/kg recipient body weight (BW) will be infused into the anterior chamber of the eye through a self-sealing incision in the peripheral cornea. The procedure is projected to take approximately 20-30 minutes. Subject will remain flat on their back for 1 - 3 hours after islet infusion to maximize adhesion of the islets to the iris.
• Patient with at least one eye with extensive loss of vision from hand motion to no light perception.
• Phakic or pseudophakic with a stable intraocular lens in the blind eye.
• Normal cornea with good visualization of the anterior segment.
• Normal anterior segment anatomy including the iris bed.
• Male and female subjects ages 18 to 75 years of age and no history of non-compliance.
• Clinical history compatible with T1D or T2D with or without insulin-dependence at the time of enrollment.
• Stable renal function of native or transplanted kidney if applicable.
• Ability to provide written informed consent.
• Mentally stable and able to comply with the procedures of the study protocol.